Portfolio Holdings Detail for ISIN IE00B441G979
| Stock Name / Fund | iShares MSCI World EUR Hedged UCITS ETF (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares V Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300QETNU1W5JY7Z94 |
| ETF Ticker | IBCH(EUR) F |
| ETF Ticker | IBCH.DE(EUR) CXE |
| ETF Ticker | IWDE.AS(EUR) CXE |
| ETF Ticker | IWDE.LS(EUR) CXE |
| ETF Ticker | IWDE.MI(EUR) CXE |
| ETF Ticker | IWDEz(EUR) CXE |
| ETF Ticker | IWDE(EUR) Euronext Amsterdam |
Holdings detail for NBIX
| Stock Name | Neurocrine Biosciences Inc |
| Ticker | NBIX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US64125C1099 |
| LEI | 549300FECER0XBN49756 |
Show aggregate NBIX holdings
News associated with NBIX
- Canaccord Genuity Group Raises Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $160.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price raised by Canaccord Genuity Group from $158.00 to $160.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. Several other brokerages have also recently commented on NBIX. Needham & Company LLC raised shares of Neurocrine Biosciences from […] - 2025-05-09 08:37:11
- Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Up on Analyst Upgrade
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) shares gapped up prior to trading on Tuesday after Royal Bank of Canada raised their price target on the stock from $137.00 to $145.00. The stock had previously closed at $109.75, but opened at $123.00. Royal Bank of Canada currently has an outperform rating on the stock. […] - 2025-05-07 06:10:42
- Investors Purchase Large Volume of Neurocrine Biosciences Put Options (NASDAQ:NBIX)
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) was the target of some unusual options trading on Monday. Investors purchased 3,005 put options on the company. This represents an increase of 325% compared to the average volume of 707 put options. Wall Street Analysts Forecast Growth NBIX has been the subject of a number of […] - 2025-05-06 05:10:52
- 2,425 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Marshall Wace LLP
- Marshall Wace LLP acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,425 shares of the company’s stock, valued at approximately $331,000. A number of other institutional investors have also […] - 2025-05-05 08:03:00
- Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $158.00 at Canaccord Genuity Group
- Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price objective reduced by research analysts at Canaccord Genuity Group from $163.00 to $158.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective would indicate a potential upside of 47.33% […] - 2025-04-30 06:00:51
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $161.14 Average Price Target from Analysts
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two brokerages that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating on the company. The average 12 month […] - 2025-04-28 06:06:49
- Wednesday's ETF with Unusual Volume: FLSP
- The Franklin Systematic Style Premia ETF is seeing unusually high volume in afternoon trading Wednesday, with over 1.1 million shares traded versus three month average volume of about 30,000. Shares of FLSP were up about 0.5% on the day.
Components of that ETF with the highest - 2025-04-16 16:12:59
- Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by Royal Bank of Canada
- Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research note issued on Monday, MarketBeat.com reports. The brokerage currently has a $137.00 price objective on the stock, down from their prior price objective of $138.00. […] - 2025-04-16 05:56:51
- UBS Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $137.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target reduced by UBS Group from $154.00 to $137.00 in a research report report published on Friday,Benzinga reports. They currently have a buy rating on the stock. A number of other analysts have also weighed in on NBIX. Royal Bank of Canada cut their target price […] - 2025-04-07 05:38:48
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $165.38 Consensus Price Target from Brokerages
- Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-three analysts that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on […] - 2025-04-03 06:06:54
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by American Century Companies Inc.
- American Century Companies Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 49.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,523 shares of the company’s stock after selling 88,727 shares during the period. American Century Companies […] - 2025-04-02 07:54:55
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Corient Private Wealth LLC
- Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,927 shares of the company’s stock after purchasing an additional 3,094 shares during the quarter. Corient Private […] - 2025-03-27 09:14:52
- Envestnet Portfolio Solutions Inc. Purchases 278 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,868 shares of the company’s stock after acquiring an additional 278 shares […] - 2025-03-27 09:14:51
- Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $184.00 at JPMorgan Chase & Co.
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price target hoisted by JPMorgan Chase & Co. from $183.00 to $184.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has an overweight rating on the stock. Several other research analysts also recently commented on NBIX. Barclays increased their price objective on Neurocrine Biosciences from […] - 2025-03-27 07:47:06
- Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com
- Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday. A number of other analysts have also recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences […] - 2025-03-14 06:12:43
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
- M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,978 shares of the company’s stock after buying an additional 1,322 shares during the quarter. […] - 2025-03-12 08:19:05
- Victory Capital Management Inc. Sells 14,309 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Victory Capital Management Inc. decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 189,896 shares of the company’s stock after selling 14,309 shares during the period. Victory Capital Management […] - 2025-03-11 08:16:52
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Charles Schwab Investment Management Inc.
- Charles Schwab Investment Management Inc. raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 762,557 shares of the company’s stock after buying an additional 15,266 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Neurocrine Biosciences were worth $104,089,000 as […] - 2025-03-10 11:50:03
- Smartleaf Asset Management LLC Grows Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- Smartleaf Asset Management LLC lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 37.2% during the fourth quarter, HoldingsChannel.com reports. The firm owned 538 shares of the company’s stock after purchasing an additional 146 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Neurocrine Biosciences were worth $74,000 as of its […] - 2025-03-10 09:10:55
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by IFP Advisors Inc
- IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,020 shares of the company’s stock after purchasing an additional 137 shares during the period. IFP Advisors Inc’s holdings […] - 2025-03-03 09:35:15
- First Horizon Advisors Inc. Has $118,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- First Horizon Advisors Inc. decreased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 865 shares of the company’s stock after selling 142 shares during the period. First Horizon Advisors Inc.’s holdings in Neurocrine Biosciences were worth $118,000 at the end […] - 2025-02-27 09:05:01
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Vontobel Holding Ltd.
- Vontobel Holding Ltd. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 42.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,442 shares of the company’s stock after selling 6,148 shares during the period. Vontobel Holding […] - 2025-02-19 09:15:16
- Neurocrine Biosciences (NASDAQ:NBIX) Earns Hold Rating from Analysts at Deutsche Bank Aktiengesellschaft
- Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Tuesday, MarketBeat reports. The brokerage issued a hold rating and a $138.00 target price on the stock. NBIX has been the subject of a number of other research reports. Needham & Company LLC restated a “hold” […] - 2025-02-14 09:04:49
- State of Alaska Department of Revenue Cuts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
- State of Alaska Department of Revenue cut its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 1.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,535 shares of the company’s stock after selling 200 shares during the quarter. State of Alaska Department […] - 2025-02-12 10:44:45
- Brokerages Set Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target at $169.20
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-three research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold recommendation, seventeen have issued a buy recommendation and one has issued a strong buy recommendation on […] - 2025-02-12 08:12:57
- Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy rating on the stock. NBIX has been the subject of several other research reports. Royal Bank of Canada decreased their price target on Neurocrine Biosciences from […] - 2025-02-11 07:12:48
- Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 4.9% After Analyst Downgrade
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00. Guggenheim currently has a buy rating on the stock. Neurocrine Biosciences traded as low as $116.48 and last traded at $116.60. 1,568,535 shares changed hands during mid-day […] - 2025-02-11 06:10:42
- Royal Bank of Canada Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $148.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its target price lowered by Royal Bank of Canada from $154.00 to $148.00 in a report released on Friday,Benzinga reports. The brokerage currently has a sector perform rating on the stock. A number of other research firms have also recently weighed in on NBIX. Canaccord Genuity Group lowered […] - 2025-02-10 16:58:49
- Canaccord Genuity Group Cuts Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $163.00
- Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective trimmed by Canaccord Genuity Group from $172.00 to $163.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Other analysts have also recently issued research reports about the stock. Raymond James restated an “outperform” rating and […] - 2025-02-10 16:58:47
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by abrdn plc
- abrdn plc boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 14.8% during the fourth quarter, Holdings Channel reports. The firm owned 156,574 shares of the company’s stock after buying an additional 20,150 shares during the quarter. abrdn plc’s holdings in Neurocrine Biosciences were worth $21,372,000 at the end of […] - 2025-02-07 09:28:53
iShares MSCI World EUR Hedged UCITS ETF (Acc) NBIX holdings
| Date | Number of NBIX Shares Held | Base Market Value of NBIX Shares | Local Market Value of NBIX Shares | Change in NBIX Shares Held | Change in NBIX Base Value | Current Price per NBIX Share Held | Previous Price per NBIX Share Held |
|---|
| 2025-05-08 (Thursday) | 6,012 | USD 626,495 | USD 626,495 | | | | |
| 2025-05-07 (Wednesday) | 6,012 | USD 643,166 | USD 643,166 | 0 | USD 12,840 | USD 106.98 | USD 104.845 |
| 2025-05-06 (Tuesday) | 6,012 | USD 630,326 | USD 630,326 | 84 | USD 56,581 | USD 104.845 | USD 96.7856 |
| 2025-05-05 (Monday) | 5,928 | USD 573,745 | USD 573,745 | 0 | USD 1,854 | USD 96.7856 | USD 96.4728 |
| 2025-05-02 (Friday) | 5,928 | USD 571,891 | USD 571,891 | 21 | USD 13,785 | USD 96.4728 | USD 94.4821 |
| 2025-05-01 (Thursday) | 5,907 | USD 558,106 | USD 558,106 | 66 | USD 4,759 | USD 94.4821 | USD 94.735 |
| 2025-04-30 (Wednesday) | 5,841 | USD 553,347 | USD 553,347 | 0 | USD 3,087 | USD 94.735 | USD 94.2065 |
| 2025-04-29 (Tuesday) | 5,841 | USD 550,260 | USD 550,260 | 84 | USD 11,645 | USD 94.2065 | USD 93.5583 |
| 2025-04-28 (Monday) | 5,757 | USD 538,615 | USD 538,615 | 21 | USD 107 | USD 93.5583 | USD 93.8821 |
| 2025-04-25 (Friday) | 5,736 | USD 538,508 | USD 538,508 | 21 | USD 7,081 | USD 93.8821 | USD 92.9881 |
| 2025-04-24 (Thursday) | 5,715 | USD 531,427 | USD 531,427 | 0 | USD 11,689 | USD 92.9881 | USD 90.9428 |
| 2025-04-23 (Wednesday) | 5,715 | USD 519,738 | USD 519,738 | 42 | USD 16,888 | USD 90.9428 | USD 88.6392 |
| 2025-04-22 (Tuesday) | 5,673 | USD 502,850 | USD 502,850 | 0 | USD 6,126 | USD 88.6392 | USD 87.5593 |
| 2025-04-21 (Monday) | 5,673 | USD 496,724 | USD 496,724 | 0 | USD -9,975 | USD 87.5593 | USD 89.3176 |
| 2025-04-18 (Friday) | 5,673 | USD 506,699 | USD 506,699 | 0 | USD 0 | USD 89.3176 | USD 89.3176 |
| 2025-04-17 (Thursday) | 5,673 | USD 506,699 | USD 506,699 | 0 | USD 7,804 | USD 89.3176 | USD 87.942 |
| 2025-04-16 (Wednesday) | 5,673 | USD 498,895 | USD 498,895 | 42 | USD 20,896 | USD 87.942 | USD 84.8871 |
| 2025-04-15 (Tuesday) | 5,631 | USD 477,999 | USD 477,999 | 42 | USD 11,458 | USD 84.8871 | USD 83.4749 |
| 2025-04-14 (Monday) | 5,589 | USD 466,541 | USD 466,541 | 0 | USD 18,622 | USD 83.4749 | USD 80.143 |
| 2025-04-11 (Friday) | 5,589 | USD 447,919 | USD 447,919 | 63 | USD -468 | USD 80.143 | USD 81.1413 |
| 2025-04-10 (Thursday) | 5,526 | USD 448,387 | USD 448,387 | 0 | USD -28,596 | USD 81.1413 | USD 86.3161 |
| 2025-04-09 (Wednesday) | 5,526 | USD 476,983 | USD 476,983 | 84 | USD 40,366 | USD 86.3161 | USD 80.231 |
| 2025-04-08 (Tuesday) | 5,442 | USD 436,617 | USD 436,617 | 21 | USD -26,197 | USD 80.231 | USD 85.3743 |
| 2025-04-07 (Monday) | 5,421 | USD 462,814 | USD 462,814 | 0 | USD -9,060 | USD 85.3743 | USD 87.0456 |
| 2025-04-04 (Friday) | 5,421 | USD 471,874 | USD 471,874 | 0 | USD -68,953 | USD 87.0456 | USD 99.7652 |
| 2025-04-02 (Wednesday) | 5,421 | USD 540,827 | USD 540,827 | 0 | USD 4,268 | USD 99.7652 | USD 98.9779 |
| 2025-04-01 (Tuesday) | 5,421 | USD 536,559 | USD 536,559 | 0 | USD -18,489 | USD 98.9779 | USD 102.388 |
| 2025-03-31 (Monday) | 5,421 | USD 555,048 | USD 555,048 | 0 | USD -11,745 | USD 102.388 | USD 104.555 |
| 2025-03-28 (Friday) | 5,421 | USD 566,793 | USD 566,793 | 0 | USD -5,530 | USD 104.555 | USD 105.575 |
| 2025-03-27 (Thursday) | 5,421 | USD 572,323 | USD 572,323 | 0 | USD -3,111 | USD 105.575 | USD 106.149 |
| 2025-03-26 (Wednesday) | 5,421 | USD 575,434 | USD 575,434 | 0 | USD -7,698 | USD 106.149 | USD 107.569 |
| 2025-03-25 (Tuesday) | 5,421 | USD 583,132 | USD 583,132 | 0 | USD 2,562 | USD 107.569 | USD 107.096 |
| 2025-03-24 (Monday) | 5,421 | USD 580,570 | USD 580,570 | 0 | USD 19,262 | USD 107.096 | USD 103.543 |
| 2025-03-21 (Friday) | 5,421 | USD 561,308 | USD 561,308 | 84 | USD 19,736 | USD 103.543 | USD 101.475 |
| 2025-03-20 (Thursday) | 5,337 | USD 541,572 | USD 541,572 | 0 | USD 316 | USD 101.475 | USD 101.416 |
| 2025-03-19 (Wednesday) | 5,337 | USD 541,256 | USD 541,256 | 21 | USD 7,564 | USD 101.416 | USD 100.394 |
| 2025-03-18 (Tuesday) | 5,316 | USD 533,692 | USD 533,692 | 0 | USD -9,030 | USD 100.394 | USD 102.092 |
| 2025-03-17 (Monday) | 5,316 | USD 542,722 | USD 542,722 | 0 | USD 1,221 | USD 102.092 | USD 101.862 |
| 2025-03-14 (Friday) | 5,316 | USD 541,501 | USD 541,501 | 0 | USD 7,894 | USD 101.862 | USD 100.378 |
| 2025-03-13 (Thursday) | 5,316 | USD 533,607 | USD 533,607 | 21 | USD 4,834 | USD 100.378 | USD 99.8627 |
| 2025-03-12 (Wednesday) | 5,295 | USD 528,773 | USD 528,773 | 0 | USD 9,207 | USD 99.8627 | USD 98.1239 |
| 2025-03-11 (Tuesday) | 5,295 | USD 519,566 | USD 519,566 | 0 | USD -22,124 | USD 98.1239 | USD 102.302 |
| 2025-03-10 (Monday) | 5,295 | USD 541,690 | USD 541,690 | 0 | USD -8,951 | USD 102.302 | USD 103.993 |
| 2025-03-07 (Friday) | 5,295 | USD 550,641 | USD 550,641 | 0 | USD -9,407 | USD 103.993 | USD 105.769 |
| 2025-03-05 (Wednesday) | 5,295 | USD 560,048 | USD 560,048 | 0 | USD -8,860 | USD 105.769 | USD 107.442 |
| 2025-03-04 (Tuesday) | 5,295 | USD 568,908 | USD 568,908 | | | | |
| 2024-11-12 (Tuesday) | 5,144 | USD 615,806 | USD 615,806 | 20 | USD 3,842 | USD 119.713 | USD 119.431 |
| 2024-11-11 (Monday) | 5,124 | USD 611,964 | USD 611,964 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NBIX by Blackrock for IE00B441G979
Show aggregate share trades of NBIX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-05-06 | BUY | 84 | | | 104.845* | | 96.10 |
| 2025-05-02 | BUY | 21 | | | 96.473* | | 96.08 |
| 2025-05-01 | BUY | 66 | | | 94.482* | | 96.12 |
| 2025-04-29 | BUY | 84 | | | 94.207* | | 96.20 |
| 2025-04-28 | BUY | 21 | | | 93.558* | | 96.28 |
| 2025-04-25 | BUY | 21 | | | 93.882* | | 96.34 |
| 2025-04-23 | BUY | 42 | | | 90.943* | | 96.60 |
| 2025-04-16 | BUY | 42 | | | 87.942* | | 97.99 |
| 2025-04-15 | BUY | 42 | | | 84.887* | | 98.45 |
| 2025-04-11 | BUY | 63 | | | 80.143* | | 99.73 |
| 2025-04-09 | BUY | 84 | | | 86.316* | | 101.07 |
| 2025-04-08 | BUY | 21 | | | 80.231* | | 101.97 |
| 2025-03-21 | BUY | 84 | | | 103.543* | | 103.12 |
| 2025-03-19 | BUY | 21 | | | 101.416* | | 103.45 |
| 2025-03-13 | BUY | 21 | | | 100.378* | | 104.96 |
| 2024-11-12 | BUY | 20 | | | 119.713* | | 0.00 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NBIX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-05-08 | 627,921 | 244 | 1,175,097 | 53.4% |
| 2025-05-07 | 713,469 | 2,722 | 1,117,874 | 63.8% |
| 2025-05-06 | 1,400,867 | 7,030 | 2,532,763 | 55.3% |
| 2025-05-05 | 296,619 | 121 | 644,954 | 46.0% |
| 2025-05-02 | 365,240 | 2,717 | 878,865 | 41.6% |
| 2025-05-01 | 334,909 | 1,718 | 414,538 | 80.8% |
| 2025-04-30 | 184,719 | 78 | 452,373 | 40.8% |
| 2025-04-29 | 188,845 | 2,237 | 268,765 | 70.3% |
| 2025-04-28 | 240,716 | 57 | 398,177 | 60.5% |
| 2025-04-25 | 383,434 | 2,042 | 564,857 | 67.9% |
| 2025-04-24 | 365,832 | 195 | 488,339 | 74.9% |
| 2025-04-23 | 458,700 | 190 | 910,605 | 50.4% |
| 2025-04-22 | 348,645 | 324 | 835,216 | 41.7% |
| 2025-04-21 | 395,831 | 361 | 658,514 | 60.1% |
| 2025-04-17 | 457,575 | 124 | 678,132 | 67.5% |
| 2025-04-16 | 965,353 | 168 | 1,358,855 | 71.0% |
| 2025-04-15 | 379,427 | 1,823 | 668,183 | 56.8% |
| 2025-04-14 | 450,911 | 249 | 754,056 | 59.8% |
| 2025-04-11 | 333,520 | 203 | 674,091 | 49.5% |
| 2025-04-10 | 472,023 | 315 | 628,440 | 75.1% |
| 2025-04-09 | 602,330 | 304 | 1,006,299 | 59.9% |
| 2025-04-08 | 436,875 | 162 | 790,249 | 55.3% |
| 2025-04-07 | 674,398 | 421 | 1,003,463 | 67.2% |
| 2025-04-04 | 539,933 | 385 | 892,094 | 60.5% |
| 2025-04-03 | 376,704 | 99 | 768,738 | 49.0% |
| 2025-04-02 | 234,959 | 215 | 551,498 | 42.6% |
| 2025-04-01 | 280,101 | 30 | 636,763 | 44.0% |
| 2025-03-31 | 216,215 | 308 | 411,408 | 52.6% |
| 2025-03-28 | 265,011 | 80 | 324,522 | 81.7% |
| 2025-03-27 | 234,011 | 41 | 308,200 | 75.9% |
| 2025-03-26 | 305,665 | 215 | 394,495 | 77.5% |
| 2025-03-25 | 314,222 | 86 | 480,625 | 65.4% |
| 2025-03-24 | 273,417 | 1,005 | 391,306 | 69.9% |
| 2025-03-21 | 332,958 | 6 | 436,521 | 76.3% |
| 2025-03-20 | 210,692 | 23 | 342,216 | 61.6% |
| 2025-03-19 | 175,559 | 72 | 288,223 | 60.9% |
| 2025-03-18 | 202,506 | 165 | 360,593 | 56.2% |
| 2025-03-17 | 212,919 | 102 | 305,435 | 69.7% |
| 2025-03-14 | 163,942 | 14,843 | 330,867 | 49.5% |
| 2025-03-13 | 178,672 | 7,541 | 288,437 | 61.9% |
| 2025-03-12 | 201,638 | 171 | 467,323 | 43.1% |
| 2025-03-11 | 231,365 | 248 | 763,188 | 30.3% |
| 2025-03-10 | 214,090 | 558 | 359,059 | 59.6% |
| 2025-03-07 | 251,531 | 5,013 | 472,743 | 53.2% |
| 2025-03-06 | 224,166 | 21 | 423,941 | 52.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.